» Articles » PMID: 21888934

Photoactivation Switch from Type II to Type I Reactions by Electron-rich Micelles for Improved Photodynamic Therapy of Cancer Cells Under Hypoxia

Overview
Specialty Pharmacology
Date 2011 Sep 6
PMID 21888934
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Photodynamic therapy (PDT) is an emerging clinical modality for the treatment of a variety of diseases. Most photosensitizers are hydrophobic and poorly soluble in water. Many new nanoplatforms have been successfully established to improve the delivery efficiency of PS drugs. However, few reported studies have investigated how the carrier microenvironment may affect the photophysical properties of photosensitizer (PS) drugs and subsequently, their biological efficacy in killing malignant cells. In this study, we describe the modulation of type I and II photoactivation processes of the photosensitizer, 5,10,15,20-tetrakis(meso-hydroxyphenyl)porphyrin (mTHPP), by the micelle core environment. Electron-rich poly(2-(diisopropylamino)ethyl methacrylate) (PDPA) micelles increased photoactivations from type II to type I mechanisms, which significantly increased the generation of O(2)(-) through the electron transfer pathway over (1)O(2) production through energy transfer process. The PDPA micelles led to enhanced phototoxicity over the electron-deficient poly(D,L-lactide) control in multiple cancer cell lines under argon-saturated conditions. These data suggest that micelle carriers may not only improve the bioavailability of photosensitizer drugs, but also modulate photophysical properties for improved PDT efficacy.

Citing Articles

An Albumin-Photosensitizer Supramolecular Assembly with Type I ROS-Induced Multifaceted Tumor Cell Deaths for Photodynamic Immunotherapy.

Zhang J, Jiao D, Qi X, Zhang Y, Liu X, Pan T Adv Sci (Weinh). 2025; 12(9):e2410405.

PMID: 39804949 PMC: 11884554. DOI: 10.1002/advs.202410405.


Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.

Cai W, Sun T, Qiu C, Sheng H, Chen R, Xie C J Nanobiotechnology. 2024; 22(1):635.

PMID: 39420366 PMC: 11488210. DOI: 10.1186/s12951-024-02925-3.


Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives.

Zhu S, Lin S, Han R Pharmaceutics. 2024; 16(9).

PMID: 39339173 PMC: 11435246. DOI: 10.3390/pharmaceutics16091135.


Self-assembly-integrated tumor targeting and electron transfer programming towards boosting tumor type I photodynamic therapy.

Chen W, Wang Z, Hong G, Du J, Song F, Peng X Chem Sci. 2024; 15(28):10945-10953.

PMID: 39027272 PMC: 11253188. DOI: 10.1039/d4sc03008g.


A Physiochemical, and Comparative Analysis of Verteporfin-Lipid Conjugate Formulations: Solid Lipid Nanoparticles and Liposomes.

Shah N, Soma S, Quaye M, Mahmoud D, Ahmed S, Malkoochi A ACS Appl Bio Mater. 2024; 7(7):4427-4441.

PMID: 38934648 PMC: 11253097. DOI: 10.1021/acsabm.4c00316.


References
1.
Roy I, Ohulchanskyy T, Pudavar H, Bergey E, Oseroff A, Morgan J . Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc. 2003; 125(26):7860-5. DOI: 10.1021/ja0343095. View

2.
Dolmans D, Fukumura D, Jain R . Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3(5):380-7. DOI: 10.1038/nrc1071. View

3.
Ochsner M . Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B. 1997; 39(1):1-18. DOI: 10.1016/s1011-1344(96)07428-3. View

4.
Vaidya A, Sun Y, Feng Y, Emerson L, Jeong E, Lu Z . Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm Res. 2008; 25(9):2002-11. PMC: 2574999. DOI: 10.1007/s11095-008-9608-1. View

5.
Blanco E, Bey E, Dong Y, Weinberg B, Sutton D, Boothman D . Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release. 2007; 122(3):365-74. PMC: 2064869. DOI: 10.1016/j.jconrel.2007.04.014. View